ISL
10.9.2019 15:21:12 CEST | Business Wire | Press release
Australian stars Kyle Chalmers, Cate and Bronte Campbell, Ariarne Titmus and Mitch Larkin will compete in a new professional league pitting the world’s best swimmers against each other in a revolutionary club-based competition, which will be shown exclusively live in Australia on 7plus.
The International Swimming League (ISL) will hold its inaugural meet in Indianapolis next month, when eight teams – four from the United States and four from Europe – will compete over two days in a full program of events over 50m to 400m.
This will be the first of seven ISL meets across the United States and Europe in 2019, with the top four teams qualifying for the final in Las Vegas in December.
With more than $5 million in prize money at stake, and most of swimming’s current Olympic champions and world-record holders set to take part, the competition will be fierce and is bound to showcase many of the captivating rivalries expected to take centre stage at the Olympic Games Tokyo 2020.
The international big names competing include Titmus’ great rival Katie Ledecky and fellow giants of the pool Adam Peaty, Sarah Sjostrom, Ryan Murphy, Federica Pellegrini, Chad le Clos and Nathan Adrian.
The Aussie contingent taking part also includes Emma McKeon, Cam McEvoy, Emily Seebohm, Clyde Lewis, Jess Hansen and Holly Barratt, giving swimming fans a chance like never before to track the progress of our brightest Olympic Games medal hopes as Tokyo 2020 draws ever closer.
Seven’s Head of Sport Saul Shtein said: “The ISL will give swimming an established place in the annual sporting calendar and offers sports fans the chance to watch the world’s best compete regularly in an exciting new format, while this inaugural season should also provide a tantalising lead-in to Tokyo 2020. We’re thrilled to bring it to our viewers and to be adding more premium live content to 7plus.”
Kontantin Grigorishin, ISL President, declared: "We are very excited about this partnership with Seven Sport, which will allow millions of fans in Australia to experience full live coverage of International Swimming League. The heart of swimming beats in Australia and will beat even stronger from October 6 with the first ever match of ISL in Indianapolis."
Swimming fans will also be able to watch highlights of every ISL meet on 7TWO and 7plus.
In 2020, Seven is the home of the Australian swimming Olympic Games trials and Tokyo 2020.
TV Broadcast times: October 6-7 ISL – Group A: Match 1 Indianapolis, USA Sydney 5.00am LIVE on 7plus Melbourne 5.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 4.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 13-14 ISL – Group A: Match 2 Naples, Italy Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
October 20-21 ISL – Group B: Match 1 Dallas, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 27-28 ISL – Group B: Match 2 Budapest, Hungary Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
November 17-18 ISL – USA Derby Washington DC, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
November 24-25 ISL – Europe Derby London, UK Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
December 21-22 ISL – Final Las Vegas, USA TBC
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005683/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom